District of Columbia Clinical Trials Report — June 2026

For residents of the District of Columbia considering participation in clinical research, June 2026 presents both urgent opportunities and significant new avenues for contribution. A total of 52 clinical trials are slated to conclude within the next 90 days, meaning the window for enrollment is rapidly closing. Among these, 5 trials are actively seeking healthy volunteers, offering a chance to contribute to medical advancements without a specific health condition.

Individuals living with certain health conditions should also act quickly to explore trials with impending deadlines. Research focusing on various cardiovascular issues, cancer, and other conditions are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Aortic valve insufficiency
• Cancer
• HIV
• Urea cycle disorder
• Spinal cord injuries
• Aortic regurgitation
• Aortic insufficiency
• Bias, racial
• Aortic valve disease
• Adult congenital heart disease

A Surge in New Research Opportunities

This month marks a notable increase in new clinical trials opening in the District of Columbia, with 13 new studies launched, a significant jump from the 7 trials that opened in May 2026. This brings the total number of recruiting trials in the District to 822 across 4 cities and 287 research sites. These new studies offer diverse opportunities, ranging from major Phase 3 drug trials to behavioral interventions, and include several notable initiatives from leading academic and industry sponsors.

The conditions addressed by these new trials are varied, reflecting a broad spectrum of health challenges. New research is now recruiting for:

• Becker muscular dystrophy
• Brain tumor
• Cardio vascular disease
• Cardiomyopathy
• Carrier of Duchenne muscular dystrophy
• Cortical blindness
• Diet quality
• Diet, healthy
• Duchenne muscular dystrophy (DMD)
• Food insecurity

Spotlight on Key New Trials

Several of this month's new trials stand out due to their scope, sponsor, or potential impact. These include significant Phase 2 and Phase 3 drug trials, as well as important behavioral and observational studies:

• Novo Nordisk A/S is sponsoring NCT07668414, a pivotal Phase 3 drug trial. This study, "A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide," aims to enroll 650 participants. It seeks to determine if zenagamtide is a safe and effective treatment for individuals with excess body weight, comparing its effects to semaglutide, a widely recognized medication.
• For those interested in cardiovascular health, AngioInsight is leading NCT07676097, "Simultaneous Measurement of EpicArdial and Microvascular ResisTance Via Angiographic FLOW Study." This observational multicenter study plans for 620 participants and aims to establish the diagnostic performance of the AngioAI+ System for estimating fractional flow reserve (FFR) and detecting coronary microvascular disease (CMD).
• In the realm of muscular dystrophies, Vanderbilt University Medical Center is sponsoring NCT07674758, "Modeling Mortality in Duchenne Muscular Dystrophy Cardiomyopathy: Identification of Surrogate Outcome Measures for DMD Drug Trials." This study, targeting 1,000 participants, seeks to better understand the evolution of heart dysfunction in patients with Duchenne and Becker Muscular Dystrophy (DMD/BMD) and carriers, which is a leading cause of death.
• Georgetown University is highly active this month, sponsoring 4 new trials. Among them is NCT07618520, "Expanding Genetic Access for Prostate Cancer Survivors," which plans to enroll 500 participants. This study aims to increase genetic education and testing for hereditary cancer risk among prostate cancer survivors by evaluating the effectiveness of digital and print guides compared to usual care.
• Another Georgetown-sponsored trial, NCT07645326, "RISK-ADAPT Protocol in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)," is a Phase 2 interventional study with 108 participants. It will assess oncologic outcomes for mCSPC patients receiving a risk-adapted treatment approach followed by treatment de-escalation within the Medstar Health network.
• For individuals experiencing persistent post-traumatic headaches, the American Society of Pain and Neuroscience, Inc. is sponsoring NCT07624279. This Phase 2 study with 80 participants investigates whether cannabidiol (CBD) or vagus nerve stimulation can reduce headache frequency more effectively than traditional oral medications.
• Addressing critical public health issues, Montefiore Medical Center is leading NCT07631598, "Buprenorphine Implementation at Syringe Service Programs to Reduce Overdoses." This study, involving 512 participants, is testing if offering buprenorphine treatment directly at syringe service programs (SSPs) can improve engagement and retention in treatment for opioid use disorder (OUD) compared to traditional referral methods.
• Globally impactful research is also represented with the International Food Policy Research Institute sponsoring NCT07640594, "Randomized Evaluation of Voucher Interventions for Value and Effectiveness (REVIVE) in Philippines." This large study, with 5,320 participants, aims to evaluate whether revised food voucher programs combined with nutrition education can improve food security, dietary quality, nutrition knowledge, and nutritional outcomes among low-income households in the Philippines.

Geographic Focus: Washington D.C. as a Research Hub

While the District of Columbia encompasses 4 cities with active clinical trials, all 13 new trials opened this month are concentrated within Washington D.C. This highlights the city's role as a primary hub for clinical research within the District, offering convenient access to cutting-edge studies for its residents. The presence of major academic institutions like Georgetown University and George Washington University, along with research institutes, contributes significantly to this concentration of research activity.

Diverse Participation and Healthy Volunteer Opportunities

Clinical trials in the District are designed to be inclusive, seeking a broad range of participants. Of the 13 new trials, 2 include children, and 11 include older adults, ensuring that research benefits diverse age groups. While no new trials are exclusively for females, 3 new trials are specifically for males.

For individuals without a specific medical condition, there are significant opportunities to contribute to medical science. Of the 13 new trials launched this month, 3 are actively seeking healthy volunteers. Statewide, a total of 93 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research and contributing to the advancement of health knowledge.

Academic institutions continue to play a vital role in the District's research ecosystem, with Georgetown University sponsoring 4 of the new trials and George Washington University sponsoring 2. Industry sponsors are also driving significant research efforts, with Novo Nordisk A/S contributing a major Phase 3 drug trial. The breakdown of new trial types this month includes 6 behavioral studies, 4 drug trials, 2 radiation studies, and 1 device trial, alongside other procedure-based research.

As we move further into June, the focus will remain on the ongoing enrollment in these diverse studies, from major drug development efforts to critical public health interventions, all contributing to the advancement of health outcomes for the District of Columbia and beyond.